[ad_1]
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is likely one of the greatest small-cap biotech shares to purchase in accordance with analysts.
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) reported its Q3 2025 outcomes on November 6, 2025. The quarter marked continued development of its muscular dystrophy and cardiac packages. In the meantime, its essential GRAND CANYON cohort for sevasemten in Becker muscular dystrophy stays well-positioned for readout in This fall 2026. On the similar time, the MESA open-label extension trial famous continued enrollment of practically all eligible members. The quarter additionally noticed the Part 2 CIRRUS-HCM trial of EDG-7500 in hypertrophic cardiomyopathy progressing effectively, with a program replace anticipated in This fall 2025. Part 1 dosing of EDG-15400 for coronary heart failure additionally kicked off.
Because of the scientific exercise in EDC-15400, EDC-7500, and the sevasemten program, R&D bills surged by $3.9 million to $37.5 million, in comparison with the identical quarter a yr earlier. With G&A bills up $0.3 million sequentially, Edgewise Therapeutics, Inc. (NASDAQ:EWTX) recorded a web lack of $40.7 million, or $0.39 per share.
But Edgewise Therapeutics, Inc. (NASDAQ:EWTX) closed the quarter with $563.3 million in money balances, adequate to supply a runway to assist ongoing scientific improvement and potential future business launches.
Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a biopharmaceutical firm, develops new therapies for muscular dystrophies and severe cardiac situations.
Whereas we acknowledge the potential of EWTX as an funding, we consider sure AI shares supply higher upside potential and carry much less draw back threat. In case you’re in search of a particularly undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring pattern, see our free report on the greatest short-term AI inventory.
READ NEXT: 7 Finest Oil and Fuel Penny Shares to Purchase In response to Analysts and Billionaire Jacob Rothschild’s RIT Capital Companions: 9 Shares with Large Upside Potential.
Disclosure: None.
[ad_2]
